OncoMatch/Clinical Trials/NCT07464132

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

Is NCT07464132 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Injection of 68Ga-NI-FAPI for tumor.

Phase 1/2RecruitingPeking Union Medical College HospitalNCT07464132Data as of May 2026

Treatment: Injection of 68Ga-NI-FAPI — The purpose of this study is to conduct clinical research on \[68Ga\] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.

Check if I qualify

Extracted eligibility criteria

Lab requirements

Kidney function

blood creatinine levels exceeding 159 μmol/L [excluded]

Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μmol/L)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify